{"pmid":32324958,"title":"Lupus anticoagulant is frequent in patients with Covid-19.","text":["Lupus anticoagulant is frequent in patients with Covid-19.","Patients hospitalized for Covid-19 severe infection are more prone to excessive coagulation activation leading to thrombotic events. Tang et al.1 discussed the importance of high D-dimer and Fibrin degradation product level to determine the patient prognostic and the risk of thrombosis. However they did not look at lupus anticoagulant (LAC). Zhang et al. described, three cases of thrombosis associated with antiphospholipid antibodies represented by anticardiolipin (aCL) and anti-beta2-glycoprotein I (abeta2GPI)2. No lupus anticoagulant was detected in any of the patients.","J Thromb Haemost","Harzallah, Ines","Debliquis, Agathe","Drenou, Bernard","32324958"],"abstract":["Patients hospitalized for Covid-19 severe infection are more prone to excessive coagulation activation leading to thrombotic events. Tang et al.1 discussed the importance of high D-dimer and Fibrin degradation product level to determine the patient prognostic and the risk of thrombosis. However they did not look at lupus anticoagulant (LAC). Zhang et al. described, three cases of thrombosis associated with antiphospholipid antibodies represented by anticardiolipin (aCL) and anti-beta2-glycoprotein I (abeta2GPI)2. No lupus anticoagulant was detected in any of the patients."],"journal":"J Thromb Haemost","authors":["Harzallah, Ines","Debliquis, Agathe","Drenou, Bernard"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324958","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jth.14867","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664895932800434176,"score":8.518259,"similar":[{"pmid":32294295,"title":"Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19.","text":["Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19.","Between February and March 2020, the Journal of Thrombosis and Hemosthasis has published four papers addressing the intricate, complex and still little understood relation between COVID-19 and thrombogenesis (1-4). ARS-Cov-2 induces in severe cases a cytokine storm that ultimately leads to the activation of the coagulation cascade, causing thrombotic phenomena (5). There is a further strong link between abnormal coagulation parameters (D-dimer and fibrin degradation products) and mortality. Tang et al. described that 71.4% of nonsurvivors and 0.6% of survivors showed evidence of disseminated intravascular coagulation (DIC), suggesting that DIC is a frequent occurrence in severe COVID-19 (4). The frequency of DIC in these patients is much higher than that reported for severe SARS (6).","J Thromb Haemost","Dolhnikoff, Marisa","Duarte-Neto, Amaro Nunes","de Almeida Monteiro, Renata Aparecida","Ferraz da Silva, Luiz Fernando","Pierre de Oliveira, Ellen","Nascimento Saldiva, Paulo Hilario","Mauad, Thais","Marcia Negri, Elnara","32294295"],"abstract":["Between February and March 2020, the Journal of Thrombosis and Hemosthasis has published four papers addressing the intricate, complex and still little understood relation between COVID-19 and thrombogenesis (1-4). ARS-Cov-2 induces in severe cases a cytokine storm that ultimately leads to the activation of the coagulation cascade, causing thrombotic phenomena (5). There is a further strong link between abnormal coagulation parameters (D-dimer and fibrin degradation products) and mortality. Tang et al. described that 71.4% of nonsurvivors and 0.6% of survivors showed evidence of disseminated intravascular coagulation (DIC), suggesting that DIC is a frequent occurrence in severe COVID-19 (4). The frequency of DIC in these patients is much higher than that reported for severe SARS (6)."],"journal":"J Thromb Haemost","authors":["Dolhnikoff, Marisa","Duarte-Neto, Amaro Nunes","de Almeida Monteiro, Renata Aparecida","Ferraz da Silva, Luiz Fernando","Pierre de Oliveira, Ellen","Nascimento Saldiva, Paulo Hilario","Mauad, Thais","Marcia Negri, Elnara"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294295","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14844","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664636192669302786,"score":322.54343},{"pmid":32302456,"title":"Potential of Heparin and Nafamostat Combination Therapy for COVID-19.","text":["Potential of Heparin and Nafamostat Combination Therapy for COVID-19.","Tang et al. recently reported that (Journal of Thrombosis and Haemostasis), in COVID-19 infections caused by the novel coronavirus (SARS-CoV-2), heparin anticoagulant therapy lowers the mortality rate in patients who present with markedly elevated concentrations of D-dimer 1). In other words, abnormal coagulation may influence the prognosis of COVID-19. This is extremely interesting. The article did not describe to what extent heparin improves the abnormal coagulation and further studies by this group are anticipated. The authors reported in that article 1) and a previous article 2) that the abnormal coagulation seen in non-survivors of COVID-19 clearly differs from the abnormal coagulation typically seen in other severe infectious diseases.","J Thromb Haemost","Asakura, Hidesaku","Ogawa, Haruhiko","32302456"],"abstract":["Tang et al. recently reported that (Journal of Thrombosis and Haemostasis), in COVID-19 infections caused by the novel coronavirus (SARS-CoV-2), heparin anticoagulant therapy lowers the mortality rate in patients who present with markedly elevated concentrations of D-dimer 1). In other words, abnormal coagulation may influence the prognosis of COVID-19. This is extremely interesting. The article did not describe to what extent heparin improves the abnormal coagulation and further studies by this group are anticipated. The authors reported in that article 1) and a previous article 2) that the abnormal coagulation seen in non-survivors of COVID-19 clearly differs from the abnormal coagulation typically seen in other severe infectious diseases."],"journal":"J Thromb Haemost","authors":["Asakura, Hidesaku","Ogawa, Haruhiko"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302456","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14858","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["D-dimer","Heparin"],"e_drugs":["Heparin","nafamostat"],"_version_":1664635401218818048,"score":252.19121},{"pmid":32304577,"title":"Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action.","text":["Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action.","Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated with coagulopathy namely disseminated intravascular coagulation, which has a rather pro-thrombotic character with high risk of venous thromboembolism. The incidence of venous thromboembolism among COVID-19 patients in Intensive Care Unit appears to be somewhat higher compared to that reported in other studies including such patients with other disease conditions. D-dimer might help in early recognition of these high-risk patients and also predict outcome. Preliminary data show that in patients with severe COVID-19, anticoagulant therapy appears to be associated with lower mortality in the subpopulation meeting sepsis-induced coagulopathy criteria or with markedly elevated d-dimer. Recent recommendations suggest that all hospitalized COVID-19 patients should receive thromboprophylaxis, or full therapeutic-intensity anticoagulation if such an indication is present.","Br J Haematol","Kollias, Anastasios","Kyriakoulis, Konstantinos G","Dimakakos, Evangelos","Poulakou, Garyphallia","Stergiou, George S","Syrigos, Konstantinos","32304577"],"abstract":["Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated with coagulopathy namely disseminated intravascular coagulation, which has a rather pro-thrombotic character with high risk of venous thromboembolism. The incidence of venous thromboembolism among COVID-19 patients in Intensive Care Unit appears to be somewhat higher compared to that reported in other studies including such patients with other disease conditions. D-dimer might help in early recognition of these high-risk patients and also predict outcome. Preliminary data show that in patients with severe COVID-19, anticoagulant therapy appears to be associated with lower mortality in the subpopulation meeting sepsis-induced coagulopathy criteria or with markedly elevated d-dimer. Recent recommendations suggest that all hospitalized COVID-19 patients should receive thromboprophylaxis, or full therapeutic-intensity anticoagulation if such an indication is present."],"journal":"Br J Haematol","authors":["Kollias, Anastasios","Kyriakoulis, Konstantinos G","Dimakakos, Evangelos","Poulakou, Garyphallia","Stergiou, George S","Syrigos, Konstantinos"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304577","week":"202016|Apr 13 - Apr 19","doi":"10.1111/bjh.16727","keywords":["sars-cov-2","anticoagulant","prophylaxis","thromboembolism","thrombosis"],"source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"locations":["thromboprophylaxis"],"_version_":1664632934588481537,"score":241.4486},{"pmid":32276140,"pmcid":"PMC7139239","title":"Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients.","text":["Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients.","Infection caused by SARS-CoV-2 can result in severe respiratory complications and death. Patients with a compromised immune system are expected to be more susceptible to a severe disease course. In this report we suggest that patients with systemic lupus erythematous might be especially prone to severe COVID-19 independent of their immunosuppressed state from lupus treatment. Specifically, we provide evidence in lupus to suggest hypomethylation and overexpression of ACE2, which is located on the X chromosome and encodes a functional receptor for the SARS-CoV-2 spike glycoprotein. Oxidative stress induced by viral infections exacerbates the DNA methylation defect in lupus, possibly resulting in further ACE2 hypomethylation and enhanced viremia. In addition, demethylation of interferon-regulated genes, NFkappaB, and key cytokine genes in lupus patients might exacerbate the immune response to SARS-CoV-2 and increase the likelihood of cytokine storm. These arguments suggest that inherent epigenetic dysregulation in lupus might facilitate viral entry, viremia, and an excessive immune response to SARS-CoV-2. Further, maintaining disease remission in lupus patients is critical to prevent a vicious cycle of demethylation and increased oxidative stress, which will exacerbate susceptibility to SARS-CoV-2 infection during the current pandemic. Epigenetic control of the ACE2 gene might be a target for prevention and therapy in COVID-19.","Clin Immunol","Sawalha, Amr H","Zhao, Ming","Coit, Patrick","Lu, Qianjin","32276140"],"abstract":["Infection caused by SARS-CoV-2 can result in severe respiratory complications and death. Patients with a compromised immune system are expected to be more susceptible to a severe disease course. In this report we suggest that patients with systemic lupus erythematous might be especially prone to severe COVID-19 independent of their immunosuppressed state from lupus treatment. Specifically, we provide evidence in lupus to suggest hypomethylation and overexpression of ACE2, which is located on the X chromosome and encodes a functional receptor for the SARS-CoV-2 spike glycoprotein. Oxidative stress induced by viral infections exacerbates the DNA methylation defect in lupus, possibly resulting in further ACE2 hypomethylation and enhanced viremia. In addition, demethylation of interferon-regulated genes, NFkappaB, and key cytokine genes in lupus patients might exacerbate the immune response to SARS-CoV-2 and increase the likelihood of cytokine storm. These arguments suggest that inherent epigenetic dysregulation in lupus might facilitate viral entry, viremia, and an excessive immune response to SARS-CoV-2. Further, maintaining disease remission in lupus patients is critical to prevent a vicious cycle of demethylation and increased oxidative stress, which will exacerbate susceptibility to SARS-CoV-2 infection during the current pandemic. Epigenetic control of the ACE2 gene might be a target for prevention and therapy in COVID-19."],"journal":"Clin Immunol","authors":["Sawalha, Amr H","Zhao, Ming","Coit, Patrick","Lu, Qianjin"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32276140","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.clim.2020.108410","keywords":["ace2","covid-19","epigenetics","interferon","lupus","methylation","sars-cov-2"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1664637190137708544,"score":229.07088},{"pmid":32267998,"title":"Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series.","text":["Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series.","A hallmark of severe COVID-19 is coagulopathy, with 71.4% of patients who die of COVID-19 meeting ISTH criteria for disseminated intravascular coagulation (DIC) while only 0.6% of patients who survive meet these criteria (1). Additionally, it has become clear that this is not a bleeding diathesis but rather a predominantly pro-thrombotic DIC with high venous thromboembolism rates, elevated D-dimer levels, high fibrinogen levels in concert with low anti-thrombin levels, and pulmonary congestion with microvascular thrombosis and occlusion on pathology in addition to mounting experience with high rates of central line thrombosis and vascular occlusive events (e.g. ischemic limbs, strokes, etc.) observed by those who care for critically ill COVID-19 patients (1-7). There is evidence in both animals and humans that fibrinolytic therapy in Acute Lung Injury and ARDS improves survival, which also points to fibrin deposition in the pulmonary microvasculature as a contributory cause of ARDS and would be expected to be seen in patients with ARDS and concomitant diagnoses of DIC on their laboratory values such as what is observed in more than 70% of those who die of COVID-19 (8-10).","J Thromb Haemost","Wang, Janice","Hajizadeh, Negin","Moore, Ernest E","McIntyre, Robert C","Moore, Peter K","Veress, Livia A","Yaffe, Michael B","Moore, Hunter B","Barrett, Christopher D","32267998"],"abstract":["A hallmark of severe COVID-19 is coagulopathy, with 71.4% of patients who die of COVID-19 meeting ISTH criteria for disseminated intravascular coagulation (DIC) while only 0.6% of patients who survive meet these criteria (1). Additionally, it has become clear that this is not a bleeding diathesis but rather a predominantly pro-thrombotic DIC with high venous thromboembolism rates, elevated D-dimer levels, high fibrinogen levels in concert with low anti-thrombin levels, and pulmonary congestion with microvascular thrombosis and occlusion on pathology in addition to mounting experience with high rates of central line thrombosis and vascular occlusive events (e.g. ischemic limbs, strokes, etc.) observed by those who care for critically ill COVID-19 patients (1-7). There is evidence in both animals and humans that fibrinolytic therapy in Acute Lung Injury and ARDS improves survival, which also points to fibrin deposition in the pulmonary microvasculature as a contributory cause of ARDS and would be expected to be seen in patients with ARDS and concomitant diagnoses of DIC on their laboratory values such as what is observed in more than 70% of those who die of COVID-19 (8-10)."],"journal":"J Thromb Haemost","authors":["Wang, Janice","Hajizadeh, Negin","Moore, Ernest E","McIntyre, Robert C","Moore, Peter K","Veress, Livia A","Yaffe, Michael B","Moore, Hunter B","Barrett, Christopher D"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267998","week":"202015|Apr 06 - Apr 12","doi":"10.1111/jth.14828","keywords":["acute respiratory distress syndrome (ards)","covid-19","case report","fibrinolysis","tissue plasminogen activator (tpa)"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664637636082401280,"score":226.09056}]}